[go: up one dir, main page]

GR1001161B - Αναστολη της προσκολλησης των λεμφοκυτταρων στο αγγειακο ενδοθηλιο με τη χρησιμοποιηση μιας αλληλεπιδρασης νεου υποδοχεα εξωκυτταρικης μητρας-προσδετη. - Google Patents

Αναστολη της προσκολλησης των λεμφοκυτταρων στο αγγειακο ενδοθηλιο με τη χρησιμοποιηση μιας αλληλεπιδρασης νεου υποδοχεα εξωκυτταρικης μητρας-προσδετη.

Info

Publication number
GR1001161B
GR1001161B GR900100648A GR900100648A GR1001161B GR 1001161 B GR1001161 B GR 1001161B GR 900100648 A GR900100648 A GR 900100648A GR 900100648 A GR900100648 A GR 900100648A GR 1001161 B GR1001161 B GR 1001161B
Authority
GR
Greece
Prior art keywords
present
receptor
adhesion
lymphocytes
inhibiting
Prior art date
Application number
GR900100648A
Other languages
English (en)
Other versions
GR900100648A (en
Inventor
Elisabeth Wayner
Original Assignee
Hutchinson Cancer Research Cen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23591680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR1001161(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchinson Cancer Research Cen filed Critical Hutchinson Cancer Research Cen
Publication of GR900100648A publication Critical patent/GR900100648A/el
Publication of GR1001161B publication Critical patent/GR1001161B/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546Integrin superfamily
    • C07K14/7055Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

H παρούσα εφεύρεση αναφέρεται σε μια μέθοδο για την αναστολή της προσκόλλησης του ενός κυττάρου σε ένα άλλο που περιλαμβάνει την παρεμβολή στην αλληλεπίδραση μεταξύ του υποδοχέα εξωκυτταρικής μήτρας και του προσδέτη του. Η εφεύρεση βασίζεται στην ανακάλυψη ότι ο α4β1 υποδοχέας εξωκυτταρικής μήτρας προάγει την προσκόλληση των λεμφοκυττάρων σε ενδοθηλιακά κύτταρα μέσω της σύνδεσης σε μια καθορισμένη πεπτιδική αλληλουχία. Πριν από την παρούσα εφέρευση, δεν είχε ταυτοποιηθεί ο προσδέτης του α4β1 υποδοχέα, ούτε ήταν γνωστή η λειτουργία του α4β1 υποδοχέα επί της λεμφοκυτταρικής προσκόλλησης. Παρεμποδίζοντας την αλληλεπίδραση μεταξύ α4β1 υποδοχέα και των προσδετών του με την χρησιμοποίηση αντισωμάτων ή καθορισμένων πεπτιδικών αλληλουχιών, η παρούσα εφεύρεση επιτρέπει, για πρώτη φορά, την ειδική παρεμβολή στην μετακίνηση των λεμφοκυττάρων μέσα από το αγγειακό ενδοθήλιο και προς τους ιστούς. Η παρούσα εφεύρεση, επομένως, έχει ιδιαίτερη κλινική χρησιμότητα στην καταστολή των ανόσων αποκρίσεων; σε διάφορες ειδικές ενσωματώσεις της εφεύρεσης, η προσκόλληση των λεμφοκυττάρων στο ενδοθήλιο μπορεί να ανασταλλεί συστηματικά, ή μπορεί, εναλλακτικά, να εντοπισθεί σε ειδικούς ιστούς ή περιγεγραμμένες επιφάνειες. Κατά συνέπεια, η παρούσα εφεύρεση προβλέπει για την θεραπεία ασθενειών που περιλαμβάνουν αυτοάνοσες αποκρίσεις όπως άλλων χρόνιων ή υποτροπιαζουσών ενεργοποιήσεων του άνοσου συστήματος, περιλαμβάνοντας αλλεργία, άσθμα, και χρόνιες φλεγμονώδεις καταστάσεις του δέρματος. ω
GR900100648A 1989-09-01 1990-08-28 Αναστολη της προσκολλησης των λεμφοκυτταρων στο αγγειακο ενδοθηλιο με τη χρησιμοποιηση μιας αλληλεπιδρασης νεου υποδοχεα εξωκυτταρικης μητρας-προσδετη. GR1001161B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40238989A 1989-09-01 1989-09-01

Publications (2)

Publication Number Publication Date
GR900100648A GR900100648A (en) 1992-01-20
GR1001161B true GR1001161B (el) 1993-05-24

Family

ID=23591680

Family Applications (2)

Application Number Title Priority Date Filing Date
GR930100041A GR1001372B (el) 1989-09-01 1990-08-28 Αναστολή της προσκόλλησης λεμφοκυττάρων στο αγγειακό ενδοθήλιο με την χρησιμοποίηση μιάς αλληλεπίδρασης νέου υποδοχέα εξωκυτταρικής μήτρας-προσδέτη.
GR900100648A GR1001161B (el) 1989-09-01 1990-08-28 Αναστολη της προσκολλησης των λεμφοκυτταρων στο αγγειακο ενδοθηλιο με τη χρησιμοποιηση μιας αλληλεπιδρασης νεου υποδοχεα εξωκυτταρικης μητρας-προσδετη.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GR930100041A GR1001372B (el) 1989-09-01 1990-08-28 Αναστολή της προσκόλλησης λεμφοκυττάρων στο αγγειακό ενδοθήλιο με την χρησιμοποίηση μιάς αλληλεπίδρασης νέου υποδοχέα εξωκυτταρικής μήτρας-προσδέτη.

Country Status (19)

Country Link
EP (2) EP0489837B2 (el)
JP (1) JP3357359B2 (el)
KR (1) KR100188459B1 (el)
AT (1) ATE253642T1 (el)
AU (1) AU654657B2 (el)
CA (1) CA2065292C (el)
DD (1) DD297562A5 (el)
DE (3) DE122006000044I2 (el)
DK (1) DK0489837T4 (el)
ES (1) ES2210225T5 (el)
FI (2) FI116793B (el)
GR (2) GR1001372B (el)
IE (2) IE903169A1 (el)
IL (3) IL113261A (el)
LU (1) LU91273I2 (el)
NL (1) NL300240I2 (el)
NZ (1) NZ235131A (el)
PT (1) PT95180A (el)
WO (1) WO1991003252A1 (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5730978A (en) * 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US7238668B1 (en) 1989-09-01 2007-07-03 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
AU3420693A (en) * 1991-12-24 1993-07-28 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
CA2127462C (en) * 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
IL102646A (en) * 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
EP0670735B1 (en) 1992-11-13 1997-04-02 Board Of Regents Of The University Of Washington Peripheralization of hematopoietic stem cells
JP3593343B2 (ja) 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
AU688307B2 (en) 1993-03-18 1998-03-12 N.V. Innogenetics S.A. Process for typing HLA-B using specific primers and probes sets
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
US5821231A (en) * 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
WO1995019790A1 (en) * 1994-01-25 1995-07-27 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
FR2724393A1 (fr) * 1994-09-12 1996-03-15 Inst Nat Sante Rech Med Obtention d'un anticorps monoclonal recombinant humanise a partir d'un anticorps monoclonal murin, sa production en cellules d'insecte, et ses utilisations
WO1997035557A1 (en) * 1996-03-22 1997-10-02 Kao Corporation External skin-care composition
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP1485127B1 (en) 2002-02-25 2011-06-08 Elan Pharmaceuticals, Inc. Administration of agents for the treatment of inflammation
US7125650B2 (en) 2004-07-20 2006-10-24 Roberts David H Method for bump exposing relief image printing plates
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP3311834A1 (en) 2011-05-02 2018-04-25 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody
EP4597110A3 (en) * 2024-02-05 2025-09-10 Universita' degli studi di Brescia Hypermobile ehlers-danlos syndrome, hypermobility spectrum disorders and osteoarthritis plasma markers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
WO1990008833A1 (en) * 1989-02-02 1990-08-09 Massachusetts Institute Of Technology Expression of recombinant fibronectin in genetically engineered cells

Also Published As

Publication number Publication date
FI920899A0 (fi) 1992-02-28
EP1366769A1 (en) 2003-12-03
GR900100648A (en) 1992-01-20
AU654657B2 (en) 1994-11-17
ES2210225T5 (es) 2014-02-04
IL113261A (en) 1996-10-16
GR1001372B (el) 1993-10-29
DD297562A5 (de) 1992-01-16
ATE253642T1 (de) 2003-11-15
PT95180A (pt) 1991-05-22
IE20040028A1 (en) 2004-05-05
JPH05503070A (ja) 1993-05-27
DK0489837T3 (da) 2004-03-01
NL300240I2 (nl) 2007-03-01
ES2210225T3 (es) 2004-07-01
FI116793B (fi) 2006-02-28
JP3357359B2 (ja) 2002-12-16
DE69034116T2 (de) 2004-08-26
FI20050941L (fi) 2005-09-21
IL113261A0 (en) 1995-07-31
KR100188459B1 (ko) 1999-06-01
EP0489837B2 (en) 2013-11-13
FI118842B (fi) 2008-04-15
KR920703086A (ko) 1992-12-17
DE69034116D1 (de) 2003-12-11
AU6354290A (en) 1991-04-08
CA2065292A1 (en) 1991-03-02
DE69034116T3 (de) 2014-06-18
LU91273I2 (fr) 2006-10-10
EP0489837A4 (en) 1993-06-16
EP0489837A1 (en) 1992-06-17
WO1991003252A1 (en) 1991-03-21
DE122006000044I2 (de) 2011-01-13
NZ235131A (en) 1993-03-26
DK0489837T4 (da) 2013-11-18
DE122006000044I1 (de) 2007-04-19
EP0489837B1 (en) 2003-11-05
IL95501A (en) 1997-04-15
NL300240I1 (nl) 2006-10-02
IE903169A1 (en) 1991-03-13
CA2065292C (en) 2001-05-29

Similar Documents

Publication Publication Date Title
GR1001161B (el) Αναστολη της προσκολλησης των λεμφοκυτταρων στο αγγειακο ενδοθηλιο με τη χρησιμοποιηση μιας αλληλεπιδρασης νεου υποδοχεα εξωκυτταρικης μητρας-προσδετη.
Mc Grath et al. Correlation between serum IgG, platelet membrane IgG, and platelet function in hypergammaglobulinaemic states
DE3586619D1 (de) Haematologische zusammensetzungen als referenz fuer drei populationen von leukocyten, verfahren zu deren herstellung und deren verwendung in ganzbluttestverfahren.
DE69112966D1 (de) Verfahren zur bestimmung von antiphospholipid antikörpern.
ATE78097T1 (de) Verfahren zur bestimmung von mimitopen.
NL300222I2 (nl) Unieke antigene epitopen op igE-dragende B-lymfocyten.
DE3750989D1 (de) Bioverträglichkeit harter flächen.
DE69019795D1 (de) Verfahren zur Feststellung der Empfindlichkeit von HIV-1 für Zidovudine und dazu geeignete Oligonukleotide.
DK21985A (da) Monoklonale antistoffer mod ikke-smaacellet lungecancer
DE69927831D1 (de) Modulierung von gedächtnis-effector t-zellen unter verwendung eines cd2-bindungsagentes
AT368854B (de) Vorrichtung zur variablen verstaerkung der elastischen abstuetzkraefte in beliebigen partialbereichen von liegemoebeln mit quer zur liegemoebelachse angeordneten federleisten
Gurewich et al. Pathogenesis of venous thrombosis in relation to its prevention by dextran and heparin
ATE205600T1 (de) Leukozytadhaesiontest
Schur Complement studies of sera and other biologic fluids
DE3852227D1 (de) Immunologisches Nachweisverfahren für Herbizide.
EA199800352A1 (ru) ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
O'Brien Neuronal adhesion molecules signal through FGF receptor
BR8106454A (pt) Suporte para saco de drenagem de liquidos corporais bem como aparelho para o recebimento e coleta de urina ou outro liquido corporal
NO963910L (no) Fremgangsmåte for bestemmelse av en suppressorkomponent av human immunstatus og en måte for gjennomföring
Grützner et al. High frequencies of PMN-MDSCs are associated with low suppressive capacity in advanced stages of HIV-1 infection
Quan et al. Spontaneous and cytokine induced basophil adhesion evaluated by microtiter assay
OHTAKA EFFECT OF ACUPUNCTURE UPON PAIN IN HANSEN'S DISEASE
Davisson Invisible owners of painted ladies and other homes: Women property owners in Nevada City, California, 1856-1876.
Bean et al. Factors That Affect the Results of Microcytotoxicity Testing in Man 1, 2, 3
Fassbender Reactions

Legal Events

Date Code Title Description
MA Right expired